Published 30 September 2015 by Juan Ramón Rallo

The decision of Martin Shkreli, the executive director of Turing Pharmaceuticals, to multiply the price of Daraprim, a drug used to treat malaria, toxoplasmosis or HIV, 55-fold has been one of the most notorious pharmaceutical scandals of recent days. The price of a Daraprim pill has gone from 13.5 USD to 750 USD. If the figures seem shocking, add to this the fact that a single Daraprim pill costs less than a USD to produce: in fact, they’re sold in India for about five cents eachContinue Reading

Source (in Spanish): www.medicossinmarca.cl/medicos-sin-marca/la-extincion-del-nino-sano/

Within the medical profession, it seems that it is not only laboratories that make systematic use of dubious promotional tactics and partnerships. In paediatrics, a common practice which is rapidly growing is the aggressive promotion of “nutraceutical” and “therapeutic” formulas – imported and very expensive.

The indiscriminate “pathologization” of normal phenomena in young infants (less than 3 months of age) and their apparent cure with hypoallergenic formulas is currently a dominant strategy. The terrain is fertile for the self-fulfilling prophecy, as phenomena that go with child development, such as crying, colic, regurgitation, night awakenings, rashes, etc., normally resolve themselves once the infant is 3 months old.Continue Reading